多囊卵巢综合征患者辅助生殖技术中未成熟卵母细胞体外成熟与控制性卵巢刺激的产科和新生儿结局
这项回顾性观察研究分析了2010年1月至2016年12月间一家三级生殖中心1036例多囊卵巢综合征(PCOS)患者的临床妊娠,其中393例单胎妊娠超过20周纳入分析。比较IVM组(164例)与COS组(229例),发现两组产科和新生儿结局总体相似,但IVM组妊娠期高血压疾病(HDP)发生率更高(29/164 (17.9%) vs 22/229 (9.6%), P=0.02),且仅PCOS表型A患者中IVM后HDP风险有升高趋势。
要点
- IVM与COS后单胎新生儿出生体重标准差评分相似(0.51 ± 0.94 vs 0.33 ± 1.05, P=0.19)。
- 未调整分析中IVM组HDP发生率高于COS组(17.9% vs 9.6%, P=0.02)。
- 仅PCOS表型A患者中IVM后HDP风险有升高趋势,需进一步研究。
核心结论
- 与COS相比,IVM似乎不不利影响PCOS患者子代的新生儿健康。
- PCOS表型A患者IVM治疗后观察到的HDP风险增加需要进一步审查。
研究设计与样本
- 回顾性观察研究,分析2010年1月至2016年12月间一家三级生殖中心1036例PCOS患者的临床妊娠数据。
- 共纳入393例妊娠超过20周的单胎妊娠,IVM组164例,COS组229例。
- PCOS诊断采用表型方法,排除卵母细胞捐赠、标准IVF(非ICSI)或胚胎植入前遗传学检测后的妊娠以及男方需睾丸活检的妊娠。
主要发现
- IVM组和COS组母亲循环AMH水平和PCOS表型分布差异显著(P < 0.001),IVM组PCOS表型A更多。
- IVM组孕妇较COS组年轻(P = 0.05)。
- 未调整分析中,IVM组母亲HDP发生率高于COS组(29/164 (17.9%) vs 22/229 (9.6%), P = 0.02)。
- IVM组和COS组单胎出生体重标准差评分相似(0.51 ± 0.94 vs 0.33 ± 1.05, P = 0.19),早产率(32-36.9周)和早期早产率(<32周)也相似。
- 单胎总畸形率IVM组为4.1%,COS组为2.4%。
关键数值与推荐
- 多变量线性回归分析显示,校正相关混杂因素后,产次是出生体重标准差评分的唯一独立预测因素(P = 0.04)。
- 多变量逻辑回归分析显示,BMI、产次和ART类型(IVM相对于COS)与HDP发生率显著相关。
- 仅PCOS表型A患者中,IVM组较COS组HDP风险有升高趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为回顾性性质。
- 部分儿童失访,无先天性畸形信息。
- 评估出生后儿童的儿科医生未对ART操作类型设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does IVM of immature oocytes retrieved from small antral follicles in women with polycystic ovary syndrome (PCOS) have an impact on obstetric and neonatal outcomes compared to controlled ovarian stimulation (COS)? SUMMARY ANSWER: Obstetric and neonatal outcomes after IVM appear to be similar to those after COS. WHAT IS KNOW ALREADY: Women with PCOS have an increased risk of adverse pregnancy outcomes and congenital malformations in their offspring. For patients with PCOS who require IVF, IVM of germinal vesicle (GV)-stage oocytes retrieved from antral follicles has been adopted as a mild approach ART, with improved pregnancy rates over the last two decades. Although reports of obstetrical and neonatal outcomes after IVM have been reassuring, the limited sample sizes in previous studies preclude firm conclusions, and further study is warranted. STUDY DESIGN, SIZE, DURATION: This is a retrospective observational study analysing obstetric and neonatal data from 1036 clinical pregnancies in unique patients with PCOS who conceived following a cycle of IVM or COS between January 2010 and December 2016 in a tertiary reproductive centre. In total, 393 singleton pregnancies with a gestational age beyond 20 weeks were included. A phenotypic approach was used for the diagnosis of PCOS. Pregnancies following oocyte donation, standard IVF (as opposed to ICSI) or preimplantation genetic testing and pregnancies requiring testicular biopsy in the male partners were excluded. PARTICIPANTS/MATERIALS,SETTING, METHODS: Pregnancy outcomes were analysed in women with PCOS phenotype A, C or D, as defined by different combinations of the Rotterdam criteria. Data from 164 pregnancies beyond 20 weeks after IVM were compared with those from 229 pregnancies after COS. Pregnancies in the IVM group were obtained after minimal ovarian stimulation and IVF with ICSI of transvaginally collected GV oocytes that had reached the metaphase II stage in vitro after 28 to 40 h of culture. No hCG trigger was administered before oocyte retrieval. Outcome measures were analysed or reported in singleton pregnancies only and included adverse obstetric events and neonatal health parameters, in particular birthweight, prematurity, small-for-gestational age, large-for-gestational age, perinatal death and major/minor malformation rates. The incidence of hypertensive disorders of pregnancy (HDP) and birthweight was analysed by multiple linear and logistic regression, adjusted for relevant treatment variables and maternal characteristics. MAIN RESULTS AND THE ROLE OF CHANCE: The IVM and the COS groups differed significantly (P < 0.001) for maternal circulating AMH levels and PCOS phenotype distribution, with more of the PCOS phenotype A in the IVM group. Pregnant women in the IVM group were younger than pregnant women in the COS group (P = 0.05). With regard to obstetric complications in singleton pregnancies, in the unadjusted analysis, mothers of infants in the IVM group more often had HDP (29/164 (17.9%) vs 22/229 (9.6%), P = 0.02) compared with mothers in the COS group. Singletons born after IVM and COS had a similar birthweight standard deviation score (SDS) (0.51 ± 0.94 after IVM vs 0.33 ± 1.05 after COS, P = 0.19). Preterm birth rate (32-36.9 weeks) and early preterm birth rate (<32 weeks) were also similar in both groups. The total malformation rate was 4.1% in singletons after IVM and 2.4% in singletons after COS. Multivariate linear regression analysis accounting for relevant confounders demonstrated that parity was the only independent predictive factor (P = 0.04) for birthweight SDS. Multivariate logistic regression analysis showed that BMI, parity and type of ART (IVM as opposed to COS) were significantly correlated with the incidence of HDP. Only patients with the PCOS phenotype A showed a tendency towards a higher risk of HDP in those who underwent IVM compared to those who had COS. LIMITATIONS, REASONS FOR CAUTION: The study is limited by its retrospective nature and loss to follow-up of a subset of children with no information regarding congenital malformations. Furthermore, the paediatricians who assessed the children after birth were not blinded for the type of ART procedure. WIDER IMPLICATIONS OF THE FINDINGS: This study provides further evidence that, compared to COS, IVM of oocytes derived from small antral follicles does not adversely affect the neonatal health of the offspring of patients with PCOS. The observed increased risk of HDP in patients with PCOS phenotype A following IVM treatment warrants further scrutiny. STUDY FUNDING/COMPETING INTEREST(S): Translational IVM research at Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB) has been supported by grants from the Institute for the Promotion of Innovation by Science and Technology in Flanders (Agentschap voor Innovatie door Wetenschap en Technologie-IWT, project 110680), the Fund for Research Flanders (Fonds Wetenschappelijk Onderzoek-Vlaanderen-FWO, project G.0343.13) and the Belgian Foundation Against Cancer (HOPE project, Dossier C69). Clinical IVM research was supported by research grants from Cook Medical and Besins Healthcare. M.D.V. reports honoraria for lectures from Cook Medical and Besins Healthcare outside the submitted work. S.S.R. reports honoraria for lectures by MSD and Besins and research grants by MSD, Ferring and Merck Serono outside of the submitted work. C.B. reports personal fees from Merck-Serono, Ferring, IBSA, Finox, MSD and Abbott outside the submitted work. H.T. reports grants from Merck, MSD, Goodlife, Cook, Roche, Besins, Ferring, Mithra (now Allergan) and the Research Fund of Flanders (FWO) and consultancy fees from Finox, Abbott, Obseva and Ovascience outside the submitted work. The other authors have nothing to disclose.
引用
- Mostinckx L, Segers I, Belva F, et al. Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation. Hum Reprod. 2019. PMID: 31347678. doi:10.1093/humrep/dez086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。